JP2006511493A5 - - Google Patents

Download PDF

Info

Publication number
JP2006511493A5
JP2006511493A5 JP2004547600A JP2004547600A JP2006511493A5 JP 2006511493 A5 JP2006511493 A5 JP 2006511493A5 JP 2004547600 A JP2004547600 A JP 2004547600A JP 2004547600 A JP2004547600 A JP 2004547600A JP 2006511493 A5 JP2006511493 A5 JP 2006511493A5
Authority
JP
Japan
Prior art keywords
tumor
antibody
pharmaceutical composition
agent
laminin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004547600A
Other languages
Japanese (ja)
Other versions
JP2006511493A (en
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2003/012012 external-priority patent/WO2004039401A2/en
Publication of JP2006511493A publication Critical patent/JP2006511493A/en
Publication of JP2006511493A5 publication Critical patent/JP2006511493A5/ja
Pending legal-status Critical Current

Links

Claims (19)

腫瘍を有する患者において腫瘍成長を抑制する医薬の製造のための、ラミニン５γ２鎖の１以上のエピトープに結合する抗体の使用。   Use of an antibody that binds to one or more epitopes of laminin 5γ2 chain for the manufacture of a medicament that inhibits tumor growth in a patient with a tumor. 前記抗体がモノクローナル抗体である、請求項１に記載の使用。   Use according to claim 1, wherein the antibody is a monoclonal antibody. 前記腫瘍が癌である、請求項１又は２に記載の使用。   The use according to claim 1 or 2, wherein the tumor is cancer. 前記医薬が、１以上のさらなる抗腫瘍薬剤をさらに含む、請求項１〜３のいずれか１項に記載の使用。   4. Use according to any one of claims 1 to 3, wherein the medicament further comprises one or more additional antitumor agents. 前記さらなる抗腫瘍薬剤が、化学療法薬剤である、請求項４に記載の使用。   Use according to claim 4, wherein the further anti-tumor agent is a chemotherapeutic agent. ラミニン５γ２鎖のドメインＩＩＩの１又は１以上のエピトープに結合するが、配列番号９及び１０のアミノ酸配列内のエピトープに結合しない単離された抗体。   An isolated antibody that binds to one or more epitopes of domain III of laminin 5γ2 chain but does not bind to an epitope within the amino acid sequence of SEQ ID NOs: 9 and 10. 前記抗体が、モノクローナル抗体である、請求項６に記載の単離された抗体。 The isolated antibody of claim 6 , wherein the antibody is a monoclonal antibody. 請求項６に記載の単離された抗体及び医薬として許容される担体を含む医薬組成物。 A pharmaceutical composition comprising the isolated antibody of claim 6 and a pharmaceutically acceptable carrier. 請求項７に記載のモノクローナル抗体を発現する単離されたハイブリドーマ細胞。   8. An isolated hybridoma cell expressing the monoclonal antibody of claim 7. 腫瘍を有する患者において腫瘍成長抑制、腫瘍転移抑制、及び浸潤細胞の検出のうちの１以上を行う医薬の製造のための、請求項６又は７に記載の単離された抗体の使用。 Use of the isolated antibody according to claim 6 or 7 for the manufacture of a medicament for performing one or more of tumor growth suppression, tumor metastasis suppression, and invasion cell detection in a patient having a tumor. ラミニン５γ２鎖のドメインIII内の１以上のエピトープに結合する抗体及びさらなる抗腫瘍薬剤を含む医薬組成物。   A pharmaceutical composition comprising an antibody that binds to one or more epitopes within domain III of laminin 5γ2 chain and a further antitumor agent. 前記さらなる抗腫瘍薬剤が化学療法薬剤である、請求項１１に記載の医薬組成物。   12. The pharmaceutical composition according to claim 11, wherein the further anti-tumor agent is a chemotherapeutic agent. 組織において浸潤細胞の存在を検出するための方法であって、
組織サンプルを請求項６又は７に記載の抗体と接触させて、免疫複合体を形成し、そして
該免疫複合体の形成を検出することを含み、ここで該免疫複合体の形成が、上記組織における浸潤細胞の存在と相関する、前記方法。 A method for detecting the presence of infiltrating cells in a tissue, comprising:
Contacting a tissue sample with the antibody of claim 6 or 7 to form an immune complex and detecting the formation of the immune complex, wherein the formation of the immune complex comprises the tissue Wherein said method correlates with the presence of infiltrating cells. 腫瘍を有する患者において腫瘍成長を抑制するための医薬組成物であって、ラミニン５γ２鎖の１以上のエピトープに結合する抗体を含む、前記医薬組成物。A pharmaceutical composition for suppressing tumor growth in a patient having a tumor, the antibody comprising an antibody that binds to one or more epitopes of laminin 5γ2 chain. 前記抗体がモノクローナル抗体である、請求項１４に記載の医薬組成物。The pharmaceutical composition according to claim 14, wherein the antibody is a monoclonal antibody. 前記腫瘍が癌である、請求項１４又は１５に記載の医薬組成物。The pharmaceutical composition according to claim 14 or 15, wherein the tumor is cancer. １以上のさらなる抗腫瘍薬剤をさらに含む、請求項１４〜１６のいずれか１項に記載の医薬組成物。The pharmaceutical composition according to any one of claims 14 to 16, further comprising one or more additional anti-tumor agents. 前記さらなる抗腫瘍薬剤が、化学療法薬剤である、請求項１７に記載の医薬組成物。18. The pharmaceutical composition according to claim 17, wherein the further anti-tumor agent is a chemotherapeutic agent. 腫瘍を有する患者における腫瘍成長抑制、腫瘍転移抑制、又は浸潤細胞の検出用の医薬組成物であって、請求項６又は７に記載の単離された抗体を含む、医薬組成物。A pharmaceutical composition for tumor growth inhibition, tumor metastasis inhibition, or detection of infiltrating cells in a patient having a tumor, comprising the isolated antibody according to claim 6 or 7.
JP2004547600A 2002-10-29 2003-10-29 Use of antibodies to laminin 5 gamma 2 chain to inhibit tumor growth and metastasis Pending JP2006511493A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42200902P 2002-10-29 2002-10-29
PCT/EP2003/012012 WO2004039401A2 (en) 2002-10-29 2003-10-29 Use of antibodies to the gamma 2 chain of lallminin 5 to inhibit tumor growth and metastasis

Publications (2)

Publication Number Publication Date
JP2006511493A JP2006511493A (en) 2006-04-06
JP2006511493A5 true JP2006511493A5 (en) 2006-12-14

Family

ID=32230306

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004547600A Pending JP2006511493A (en) 2002-10-29 2003-10-29 Use of antibodies to laminin 5 gamma 2 chain to inhibit tumor growth and metastasis

Country Status (6)

Country Link
EP (1) EP1578444A2 (en)
JP (1) JP2006511493A (en)
AU (1) AU2003286142A1 (en)
CA (1) CA2502088A1 (en)
MX (1) MXPA05004126A (en)
WO (1) WO2004039401A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005040219A1 (en) * 2003-10-28 2005-05-06 Novo Nordisk A/S Laminin-5 gamma2-binding peptides, related compositions, and use thereof
WO2005052003A2 (en) * 2003-11-20 2005-06-09 Biostratum, Inc. Use of antibodies to the gamma 2 chain of laminin 5 to inhibit tumor growth and metastasis
JP2012530045A (en) * 2008-06-18 2012-11-29 カール トゥリッグバソン， Antibodies against the domain of laminin-332
US20140045196A1 (en) * 2012-08-13 2014-02-13 University Of Tokyo Methods of prognosis and diagnosis of cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5660982A (en) * 1994-10-04 1997-08-26 Tryggvason; Karl Laminin chains: diagnostic uses
US6955924B2 (en) * 1994-10-04 2005-10-18 Biostratum, Inc. Laminin chains: diagnostic uses
EP1326892A2 (en) * 2000-10-12 2003-07-16 University of Rochester Compositions that inhibit proliferation of cancer cells
EP1424558A4 (en) * 2001-08-17 2004-12-15 Eisai Co Ltd Reagent for assaying laminin 5 antigen in biological sample and assay method

Similar Documents

Publication Publication Date Title
Lecavalier‐Barsoum et al. Targeting the CXCL12/CXCR4 pathway and myeloid cells to improve radiation treatment of locally advanced cervical cancer
AU2016206682B2 (en) Treatment of cancer with anti-LAP monoclonal antibodies
CA2786417C (en) Methods for treating colorectal cancer
JP2009539380A5 (en)
JP2008532523A5 (en)
JP2009529497A5 (en)
JP2013531655A5 (en)
JP2010510809A5 (en)
JP2015533788A5 (en)
JP2009197002A5 (en)
JP2007504280A5 (en)
JP2013518903A5 (en)
JP2010513303A5 (en)
JP2010533498A5 (en)
JP2020536109A5 (en)
JP2014512812A5 (en)
JP2009505676A5 (en)
TW200940093A (en) Methods and agents for the diagnosis and treatment of hepatocellular carcinoma
JP2016520520A5 (en)
JP2002532079A5 (en)
Wang et al. PARP-1 promotes tumor recurrence after warm ischemic liver graft transplantation via neutrophil recruitment and polarization
JP2008516985A5 (en)
JP2006511493A5 (en)
JP2009540278A5 (en)
AU2020200574A1 (en) Methods and products for preventing and/or treating metastatic cancer